Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Recursion Pharmaceuticals (RXRX) recently experienced a share price increase of 14% over the last month. This upward movement comes amid a flat broader market trend in the last week and coincides ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier ...

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.

Lunawat, a chartered accountant by training, is the first Indian woman to independently set up and receive Sebi approval for a non-institutional mutual fund house, a release from the company said.

Looking to invest for the long haul? Discover mutual fund strategies and high-conviction schemes aligned with India’s growth story for the next decade.

Kotak Mahindra Asset Management integrates with ONDC to democratize mutual fund investments, targeting Tier 2 and Tier 3 cities.

Alligator Alcatraz, the migrant detention center in the Florida Everglades, is surrounded by swamps infested with massive Burmese pythons.

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter ...

Highest-return mutual funds in 20 years: Nippon India funds top return chart, turn Rs 1 lakh into Rs 35 lakh Over the past 20 years, a few standout mutual funds from Nippon India have delivered ...